Geode Capital Management
CLDI icon

Geode Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Geode Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.5K Buy
7,159
+3,220
+82% +$10.4K ﹤0.01% 4377
2026
Q1 		$15K Buy
3,939
+1,318
+50% +$15.8K ﹤0.01% 4473
2025
Q4 		$49.1K Buy
2,621
+771
+42% +$18.1K ﹤0.01% 4240
2025
Q3 		$45K Buy
1,850
+639
+53% +$43.4K ﹤0.01% 4316
2025
Q2 		$53.5K Sell
1,211
-101
-8% -$7.85K ﹤0.01% 4201
2025
Q1 		$143K Buy
1,312
+479
+58% +$87.4K ﹤0.01% 3936
2024
Q4 		$184K Buy
833
+627
+304% +$188K ﹤0.01% 3930
2024
Q3 		$45.2K Buy
+206
New +$57.3K ﹤0.01% 4284
2024
Q2 		– Sell
-56
Closed -$60.5K – 4592
2024
Q1 		$60.5K Buy
56
+3
+6% +$4.9K ﹤0.01% 4283
2023
Q4 		$154K Buy
+53
New +$228K ﹤0.01% 4029

Other funds holding CLDI

HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
RCI
RS Crum Inc Newport Beach, California $533M AUM 20.75% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BAM
Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management's CLDI Position: Q2 2026 in Review

Geode Capital Management increased its Calidi Biotherapeutics (CLDI) stake by 82% in Q2 2026, buying an estimated $10.4K and bringing the position to 7,159 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4377.

Geode Capital Management first reported a position in CLDI in Q4 2023 and has held it in 10 quarters since. The position peaked at $184K in Q4 2024. 22 funds tracked by Wall St. Rank hold CLDI as of Q2 2026.

  • Geode Capital Management held 7,159 shares of Calidi Biotherapeutics worth $19.5K as of Q2 2026.
  • Geode Capital Management bought 3,220 Calidi Biotherapeutics shares in Q2 2026, an estimated $10.4K.
  • Calidi Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4377 holding.
  • Geode Capital Management first reported a position in Calidi Biotherapeutics in Q4 2023 and has held it in 10 quarters since.
  • Geode Capital Management's Calidi Biotherapeutics position peaked at $184K in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.